Ultragenyx Pharmaceutical Inc
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Capital expenditures decreased by 14% from FY24 to FY25.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedUltragenyx Pharmaceutical Inc (RARE) Insider Trades
RARE Insider Trading Activity
Track insider trading transactions for Ultragenyx Pharmaceutical Inc (RARE). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $24.77. Market cap: $2.39B. This page displays the most recent insider transactions for RARE, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Ultragenyx Pharmaceutical Inc's investment outlook.